The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center; IAVI, New York, NY
International AIDS Vaccine Initiative; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
International AIDS Vaccine Initiative; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
BG505 SOSIP.664 is a well-characterized near-native recombinant HIV Envelope (Env) trimer that holds promise as part of a sequential immunogen regime for an HIV vaccine. BG505 has been tested in many preclinical animal models and is now in first-in-human phase I clinical trials. Rhesus macaques are considered the most similar in terms of nAb responses to humans. Accordingly, we report here the isolation of 45 BG505 nAbs with multiple specificities from immunized and infected rhesus macaques.Notably, all of the autologous nAbs bind in close proximity to known bnAb epitopes and might therefore sterically hinder elicitation of bnAbs. Finally, we identify a “public clonotype” that targets the immunodominant C3/V5 epitope, which suggests that such common rearrangements might greatly influence immunodominant humoral responses to Env immunogens. The results highlight important considerations for vaccine design in anticipation of results of the BG505 SOSIP.664 trimer in human clinical trials.
Zhao, Fangzhu and Joyce, Collin and Burns, Alison and Nogal, Bartek and Ramos, Alejandra and Biddle, Trevor and Pauthner, Matthias and Nedellac, Rebecca and Qureshi, Huma and Mason, Rosemarie and Landais, Elise and Ward, Andrew B. and Burton, Dennis R. and Sok, Devin, Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. Available at SSRN: https://ssrn.com/abstract=3578689 or http://dx.doi.org/10.2139/ssrn.3578689
This version of the paper has not been formally peer reviewed.
Download This Paper
There are 2 versions of this paper